Finland· FI-REL-REL59144
Enjaymo
A sutimlimab product containing sutimlimab, registered in Finland by Recordati Rare Diseases. The same ATC class is registered in 9 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Sutimlimab is registered in 9 of 19 countries.
Countries holding a registration under ATC L04AJ04 (sutimlimab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Sutimlimab · ATC L04AJ04
9 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Sutimlimab
- Manufacturer
- Recordati Rare Diseases
- Country
- Finland (FI)
- ATC code
- L04AJ04
- ATC class
- Sutimlimab
- Defined daily dose
- 0.46 g, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sutimlimab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandEnjaymo 1100 mg/22 ml, InfusionslösungRECORDATI AG
- CzechiaENJAYMORecordati Rare Diseases, Puteaux
- IrelandEnjaymo 50 mg/mL solution for infusionRecordati Rare Diseases
- IcelandEnjaymoRecordati Rare Diseases
- NorwayEnjaymoRecordati Rare Diseases
- PolandEnjaymoSanofi B.V.
- BelgiumEnjaymo 50 mg/mlRecordati Rare Diseases
- SwedenEnjaymo 50 mg/mL Infusionsvätska, lösningRecordati Rare Diseases
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Enjaymo
- Liechtenstein · Enjaymo
- Norway · Enjaymo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7407ebeb-eb08-4292-ac75-ca507a39f16c GET /v1/drugs/7407ebeb-eb08-4292-ac75-ca507a39f16c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.46",
"form": "infuusioneste, liuos",
"route": "Laskimoon",
"ddd_unit": "g",
"strength": "50 mg/ml",
"atc_label": "sutimlimabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/22/1687/001-002",
"fimea_rel_id": "REL59144",
"authorised_at": "2022-11-15"
}See everything about sutimlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.